Respiratory device maker Electromed Q1 revenue rises on higher growth in hospital, distributor markets

Electromed

12/11/2025 21:27

Overview

Electromed Q1 FY 2026 revenue grows 15.1% yr/yr to $16.9 mln

Net income rises 44.9% to $2.1 mln, reflecting strong operational execution

Company authorized $10 mln stock repurchase in Q1

Outlook

Electromed expects manufacturing optimization to support future growth

Company anticipates CRM system to boost sales productivity

Electromed aims for attractive returns in fiscal 2026 and beyond

Result Drivers

SALES TEAM EXPANSION - Increase in direct sales representatives and higher net revenues per representative drove revenue growth

HOSPITAL AND DISTRIBUTOR GROWTH - Significant revenue growth in hospital and distributor markets contributed to overall revenue increase

OPERATIONAL EFFICIENCIES - Improved efficiencies and new CRM system enhanced sales productivity and profitability

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$16.9 mln
Q1 EPS
$0.25
Q1 Net Income
$2.1 mln
Q1 Operating Income
$2.7 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Electromed Inc is $35.50, about 31.8% above its November 10 closing price of $24.20

Press Release: ID:nBw8lN4x1a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)